DTC User Fee Program’s Demise Leaves Advertisers Bobbing In Its Wake

FDA's formal termination of the user fee program for review of direct-to-consumer advertising does not resolve the regulatory uncertainty surrounding the ads. Sponsors are now faced with the prospect of stricter penalties for advertising violations without an expedited means of obtaining immunity from them

More from Archive

More from Pink Sheet